Drug intelligence / Profile preview

ISO-1 F-18

Development stage: Phase 1
Lead developer: University of Pennsylvania
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ISO-1 F‑18 is a radioconjugate consisting of the benzamide analog ISO‑1 labeled with the positron-emitting radioisotope fluorine‑18. It acts as a sigma‑2 receptor ligand, targeting sigma‑2 receptors that are expressed at higher density in proliferating tumor cells compared to quiescent cells. This property enables its use as a positron emission tomography (PET) tracer for evaluating tumor proliferation in patients with malignant neoplasms, particularly breast cancer. The drug is investigational and has been studied in Phase 1 clinical trials for imaging cellular proliferation in tumors using PET[3][4][7][1].

Other names: Fluorine F 18 ISO-1

Targets

TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))

Beyond the preview

Go deeper on ISO-1 F-18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISO-1 F-18.

Explore the full profile